Evaxion Biotech up on trial data on cancer therapy

Evaxion A/S

17/11/2022 15:37

** Shares of Evaxion Biotech A/S  EVAX.O  gain as much as
6.3% to $2.35 
    ** Co reports interim data from early-to mid-stage study of
its experimental cancer immunotherapy, EVX-02; says all patients
showed a specific T-cell immune response induced by the
treatment
    ** Adds that the T-cell responses were robust and long
lasting
    ** Treatment appeared to be well tolerated in all patients,
with only very mild adverse events - EVAX
    ** Full clinical trial report for EVX-02's early-stage study
 expected in Q2 of 2023 - EVAX
    ** Including session moves, stock down ~50% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))